Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 9/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538526 | 0.85 | L3MBTL1 (0.46) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL29954630 | 0.85 | L3MBTL1 (0.46) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL427889 | 0.79 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL9945959 | 0.79 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL255559 | 0.78 | L3MBTL1 (0.72) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL8996035 | 0.77 | L3MBTL1 (0.51) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL12648399 | 0.77 | L3MBTL1 (0.51) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL13696485 | 0.77 | L3MBTL1 (0.51) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL3316374 | 0.77 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 | |
| SCHEMBL29952625 | 0.77 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2C19CYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | L3MBTL1 4393/4885CYP1A2 2891/4885CYP2C19 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.